Trisol Medical's Positive Feasibility Study Findings on Tricuspid Valve System

Trisol Medical, an Israel-based company, announced favorable results from its U.S. Early Feasibility Study for their Transcatheter Tricuspid Valve Replacement (TTVR) system. This study targets severe tricuspid regurgitation (TR), where the valve fails to close properly, often leaving limited treatment options. The FDA-approved study involved 22 high-risk patients who underwent the procedure at various leading U.S. medical centers using a trans-jugular access approach.

The study highlighted several key outcomes: less than 5% needed a permanent pacemaker at 30 days, notable reductions in TR, and improvements in quality of life and heart function. Successful device deployment without incidents of migration was reported. These findings are especially significant for patients with reduced right ventricular function.

Trisol's CEO, Ron Davidson, expressed enthusiasm, affirming the technology's potential in enhancing care for severe TR patients.